Diffuse Large B Cell Lymphoma (DLBCL) is the most common Non-Hodgkin Lymphoma in Western countries and is comprised of a heterogeneous group of biologically distinct entities resulting in the clonal proliferation of a germinal or post-germinal malignant B cell. The disease is particularly aggressive with 40% of the afflicted individuals succumbing to the disease.
The standard treatment for DLBCL is still chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Whilst this modality is safe and effective, up to 45%–50% of patients will relapse. Despite advances in therapy, DLBCL remains a challenging disease to manage, with significant heterogeneity in clinical presentation and outcomes. Therefore, there is a need to update the medical community with the latest updates in the diagnosis and treatment of DLBCL.
This Research Topic aims to address various aspects of DLBCL management, including diagnosis, prognostic factors, and treatment options. We welcome submissions on, but not limited to:
- The role of immunotherapy and cellular therapies in the management of DLBCL
- New and emerging treatment options and improving the prognostic outlook for patients.
- Updates and discoveries surrounding new subtypes of DLBCL and co-morbidity of DLBCL with other debilitating factors and diseases.
- Novel predictive biomarkers, prognostic factors, and risk stratification
- Updates on the genetic and molecular landscape of DLBCL
- Management of relapsed/refractory disease
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Diffuse Large B Cell Lymphoma (DLBCL) is the most common Non-Hodgkin Lymphoma in Western countries and is comprised of a heterogeneous group of biologically distinct entities resulting in the clonal proliferation of a germinal or post-germinal malignant B cell. The disease is particularly aggressive with 40% of the afflicted individuals succumbing to the disease.
The standard treatment for DLBCL is still chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Whilst this modality is safe and effective, up to 45%–50% of patients will relapse. Despite advances in therapy, DLBCL remains a challenging disease to manage, with significant heterogeneity in clinical presentation and outcomes. Therefore, there is a need to update the medical community with the latest updates in the diagnosis and treatment of DLBCL.
This Research Topic aims to address various aspects of DLBCL management, including diagnosis, prognostic factors, and treatment options. We welcome submissions on, but not limited to:
- The role of immunotherapy and cellular therapies in the management of DLBCL
- New and emerging treatment options and improving the prognostic outlook for patients.
- Updates and discoveries surrounding new subtypes of DLBCL and co-morbidity of DLBCL with other debilitating factors and diseases.
- Novel predictive biomarkers, prognostic factors, and risk stratification
- Updates on the genetic and molecular landscape of DLBCL
- Management of relapsed/refractory disease
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.